ADIAL PHARMACEUTICALS, INC. — Form 10-Q/A
Filed October 20, 2026 · analyzed by the Periodic Agent
10-Q/A
— Neutral
significance 8/100
What the filing says
This is Amendment No. 1 to a quarterly report (10-Q) for period ended June 30, 2026, filed October 20, 2026. The document contains only boilerplate Sarbanes-Oxley certifications from CEO Cary J. Claiborne and CFO Vinay Shah attesting to financial statement accuracy and internal control effectiveness. No substantive business changes, financial data, or material events are disclosed in the provided excerpts.
Why this rating
Routine amended filing with standard certifications. No operational, financial, or strategic changes disclosed. Administrative in nature; does not alter business trajectory.
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.